Abivax postpones the publication of the yearly universal registration document ("URD")
PARIS, France April 29, 2020 - 08:00 p.m. (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today postponed the release of its yearly "Universal Registration Document 2020 (URD)" due to technical reasons caused by the COVID-19 pandemic.
The Company is carrying out an in-depth analysis of potential risks, as well as newly emerging opportunities, considering the recent COVID-19 related developments. In order to be able to provide a complete Company update, the universal registration document will be released by the end of May at the latest in accordance with the exceptional regulatory guidelines relating to COVID-19.
About Abivax ()
Abivax is mobilizing the body's natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 - Mnémo: ABVX). More information on the company is available at Follow us on Twitter @ABIVAX_.
Contacts
Abivax
Finance
Didier Blondel
41 |
Abivax
Communications
Regina Jehle
63 |
Investors
LifeSci Advisors
Chris Maggos
|
Press Relations & Investors Europe
MC Services AG
Anne Hennecke
22 |
Public Relations France
Actifin
Ghislaine Gasparetto
22 |
Public Relations USA
Rooney Partners LLC
Marion Janic
|
Â
DISCLAIMER
This press release contains forward-looking statements, forecasts and estimates with respect to certain of the Company's programs. Although the Company believes that its forward-looking statements, forecasts and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors that have been deemed reasonable, such forward-looking statements, forecasts and estimates are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in such forward-looking statements, forecasts and estimates. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its registration document (Document de Référence). Furthermore, these forward-looking statements, forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law.
This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction, in particular in France. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgement. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.
29.04.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at
